Haleon PLC Sponsored ADR $HLN Shares Acquired by Savant Capital LLC

Savant Capital LLC lifted its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 249.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 113,228 shares of the company’s stock after buying an additional 80,831 shares during the quarter. Savant Capital LLC’s holdings in Haleon were worth $1,145,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. National Bank of Canada FI raised its stake in shares of Haleon by 6.7% during the 3rd quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock worth $156,000 after buying an additional 1,099 shares during the period. Oppenheimer & Co. Inc. raised its stake in shares of Haleon by 4.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock worth $250,000 after buying an additional 1,100 shares during the period. Cary Street Partners Financial LLC raised its stake in shares of Haleon by 20.1% during the 2nd quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock worth $69,000 after buying an additional 1,113 shares during the period. Advisory Services Network LLC raised its stake in shares of Haleon by 7.1% during the 3rd quarter. Advisory Services Network LLC now owns 17,431 shares of the company’s stock worth $156,000 after buying an additional 1,155 shares during the period. Finally, Geneos Wealth Management Inc. increased its position in shares of Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares in the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HLN has been the subject of several recent research reports. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Argus raised Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Read Our Latest Analysis on Haleon

Haleon Stock Down 2.6%

Shares of NYSE:HLN opened at $8.83 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The business has a fifty day moving average of $9.51 and a two-hundred day moving average of $9.95. The stock has a market cap of $39.09 billion, a P/E ratio of 22.63, a PEG ratio of 2.06 and a beta of 0.13. Haleon PLC Sponsored ADR has a 52-week low of $8.71 and a 52-week high of $11.42.

Haleon (NYSE:HLN – Get Free Report) last issued its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The company had revenue of $3.65 billion during the quarter. On average, research analysts expect that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Haleon Company Profile

(Free Report)

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.

Further Reading

• Five stocks we like better than Haleon
• Why These Three Big Buybacks Are Sending Very Different Signals to Investors
• Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
• Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
• Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?

Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon PLC Sponsored ADR (NYSE:HLN – Free Report).